TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

Jang Ho Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.